Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment

• Main Authors: Hong Kyung Taek, Kang Hyoung Jin, Kim Nam Hee, Kim Min Sun, Lee Ji Won, Kim Hyery, Park Kyung Duk, Shin Hee Young, Ahn Hyo Seop
• Format: Article
• Language: English
• Published: BMC 2012-03-01
• Series: Journal of Hematology & Oncology
• Subjects: Plerixafor; Hematopoietic Stem Cell Mobilization; Pediatrics; Complications; Interstitial Lung Diseases
• Online Access: http://www.jhoonline.org/content/5/1/14

<p>Abstract</p> <p>Peripheral blood stem cell (PBSC) mobilization, which uses plerixafor (AMD 3100), a newly developed specific inhibitor of the CXCR4 receptor, in combination with granulocyte-colony stimulating factor(G-CSF), has been shown to enhance the stem cell mobilization in adult patients, but pediatric data are scarce. We documented our experience with this drug in 6 Korean pediatric patients who had failed in chemomobilization, using G-CSF, alone. All patients were mobilized CD34⁺cells (median, 11.08 × 10⁶/kg: range, 6.34-28.97 × 10⁶/kg) successfully within 2 to 3 cycles of apheresis, without complications. A total of 7 autologous transplantations were performed, including 1 tandem transplantation. However, 2 patients with brain tumors showed severe pulmonary complications, including spontaneous pneumomediastinum. This is the first study of PBSC mobilization with plerixafor in Asian pediatric patients. Furthermore our study suggests that mobilization with plerixafor may be effective in Korean pediatric patients, who have previously been heavily treated and have failed PBSC mobilization with classical chemomobilization, using G-CSF. However, further studies are needed to examine the possible complications of autologous transplantation, using a mobilized plerixafor product in children.</p>